Evonik sells superabsorbents business to International Chemical Investors Group, with final transfer of business planned for mid-2024; superabsorbents business no longer fits Evonik's character as a specialty chemicals company, CEO says

Sample article from our Transformation & Innovation

March 4, 2024 (press release) –

Jörg Wagner
Head of External Communications 
Richard Weiss
External Communications 
  • ICIG acquires production facilities at five locations in Germany and U.S.
  • Purchase price in low triple-digit million euro range
  • Closing expected for mid-2024 following approval by competition authorities

Essen, Germany. Evonik is selling its superabsorbents business to the International Chemical Investors Group (ICIG). A corresponding agreement has been signed, and employees at the German sites were the first to be informed accordingly this morning. The purchase price (enterprise value) is in the low triple-digit million euro range. The agreement also includes the assumption of pension obligations by ICIG. The final transfer of the business is planned for mid-2024 following approval by the relevant competition authorities.

"In terms of its profile, the superabsorbents business no longer fits our character as a specialty chemicals company," says Christian Kullmann, CEO of Evonik. "We have sought and found a reliable investor for it. Our company is thus taking the second step in the divestment of our Performance Materials Division."

ICIG is an experienced chemical investor based in Frankfurt am Main, Germany. With more than 6,200 employees, the group generates annual sales of over €4.6 billion. "We are delighted to be able to take over another business from Evonik," says Dr. Achim Riemann, Chairman of the Supervisory Board of ICIG. "With its high technological quality as a new platform within ICIG, the Superabsorbents business will offer our Group new opportunities for further growth."

ICIG has extensive expertise in the development of sites and business units that are no longer part of the core business at corporate groups. In April 2023, ICIG had already acquired the Luelsdorf site and associated businesses in Wesseling from Evonik and announced extensive investments there. Like the superabsorbent business, the site previously belonged to the Performance Materials Division. Its third part are chemicals from the C4 chain, a business that is also up for sale.

Superabsorbents are powdered polymers used as absorbent materials in diapers and other hygiene products. The business to be sold generated sales of €892 million in 2023, with adjusted EBITDA in the mid double-digit million euro range. On average over the past five years, it had achieved an adjusted EBITDA of around €20 million. ICIG is taking over the entire business with around 1,000 employees and superabsorber production facilities in Krefeld and Rheinmuenster, Germany, as well as two locations in the U.S. in Greensboro, North Carolina, and Garyville, Louisiana. The business also includes plants in Marl, Germany, for production of acrylic acid, the most important raw material for superabsorbents.

For Thomas Wessel, Chief Human Resources Officer and Labor Director at Evonik, choosing ICIG is a logical choice. "ICIG has already proven to be a trustworthy partner in Luelsdorf that also keeps all its promises to employees," says Wessel. "We know from experience that the superabsorber business is in good hands. Our employees will have a good new home with the Group." Martin Albers, Chairman of the General Works Council, is also satisfied: "ICIG is an experienced investor that respects employee rights and acts responsibly. We are convinced that we have again found a suitable investor for the superabsorber business who will offer its staff secure and future-oriented jobs."

Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €15.3 billion and an operating profit (adjusted EBITDA) of €1.66 billion in 2023. Evonik goes far beyond chemistry to create innovative, profitable, and sustainable solutions for customers. More than 33,000 employees work together for a common purpose: We want to improve life today and tomorrow.

International Chemical Investors Group is a privately owned industrial group with a total turnover of more than €4.6 billion. ICIG focuses on several main platforms: Fine Chemicals under the WeylChem brand, Care Chemicals (Catexel), Chlorovinyls (Vynova), Compounds (Benvic), Hydrocarbons & Solvents (HCS Group) and Enterprises with specialized businesses in sodium metals, industrial drying services, fermentation products, viscose filaments, activated carbon and wood protection chemicals. Today, the ICIG companies employ more than 6,200 people and operate more than 42 production sites in Europe and the U.S.

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.

* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.

See our dashboard in action - schedule an demo
Chelsey Quick
Chelsey Quick
- VP Client Success -

We offer built-to-order transformation & innovation coverage for our clients. Contact us for a free consultation.

About Us

We deliver market news & information relevant to your business.

We monitor all your market drivers.

We aggregate, curate, filter and map your specific needs.

We deliver the right information to the right person at the right time.

Our Contacts

1990 S Bundy Dr. Suite #380,
Los Angeles, CA 90025

+1 (310) 553 0008

About Cookies On This Site

We collect data, including through use of cookies and similar technology ("cookies") that enchance the online experience. By clicking "I agree", you agree to our cookies, agree to bound by our Terms of Use, and acknowledge our Privacy Policy. For more information on our data practices and how to exercise your privacy rights, please see our Privacy Policy.